Scientists from ITMO University have developed magnetically-driven nanoparticles containing thrombin. A drug based on these nanoparticles can be injected intravenously and delivered straight to the site of a vascular injury to stop internal bleeding. It can accelerate local clot formation and reduce overall blood loss by up to 15 times. The nanoparticles are not toxic to humans and can potentially be used for safe treatment.
The results were published in Scientific Reports.
Internal bleeding is a serious medical emergency. It may be caused by numerous medical conditions such as traumas or chronic diseases and it occurs in various body parts including the brain or the stomach. Yet the prognosis for majority of cases is quite pessimistic, as internal bleeding usually causes hematomas, organ dysfunction and massive blood loss. Although there are several drugs that can stop severe blood loss, none of them can help entirely without surgical intervention. In an attempt to stop bleeding more effectively, scientists are developing drugs that can be applied using a simple injection. The main issue with such drugs is that the remedy has to initiate clot formation only at the site of vessel damage instead of affecting the entire vascular system.
In a new study, scientists from ITMO University suggested using magnet-driven nanoparticles to solve this problem. The particles consist of two key components. The first is thrombin, an enzyme responsible for blood clotting. It interacts with the protein called fibrinogen and triggers clot formation in order to block the damaged vessel. The thrombin is wrapped into a special porous matrix made of magnetite. This mineral is the second main ingredient and allows for precise control of the movement of particles inside the body using an external magnetic field.
Magnetic nanoparticles with thrombin have low activity and do not cause blood clotting if they are evenly distributed in blood vessels. Therefore it is possible to inject a solution of particles intravenously and localize them where needed using a magnet. When the patient receives an extra portion of fibrinogen, thrombin particles around the site of injury interact with it and the bleeding stops faster.
“We tested the nanoparticles’ efficiency on human blood plasma samples and a special vessel model,” says Andrey Drozdov, member of SCAMT Laboratory at ITMO University. “After the first experiments with plasma, we found out that thrombin in our nanoparticles is less active compared to its free variant. Yet we went on with the tests and ran additional experiments on a model of the blood stream. We were able to observe how nanoparticles behave when the vessel is damaged. It turned out that magnetic localization compensates for lower activity. Nanoparticles reduce the clotting time by 6.5 times and can reduce total blood loss by 15 times.”
“Synthesizing these nanoparticles is not easy,” says head of the laboratory Vladimir Vinogradov. “It is important to keep their size down to 200 nanometers; otherwise they will not be suitable for injection. In addition, mild synthesis conditions are required so that the thrombin molecule does not break down and lose its activity completely. Finally, we could only use biocompatible components. We checked the toxicity of our particles with human cells and made sure they are completely safe even during prolonged exposure.”
This work is part of a larger project aiming to create hybrid nanomaterial-based hemostatic drugs. Scientists are currently planning to test the drug based on the obtained material on animal models and, in case of success, run clinical trials. Researchers hope to create a nanoparticle-based hemostasis system that will be able to quickly and efficiently stop internal bleeding
The Latest on: Nanoparticle-based hemostasis system
via Google News
The Latest on: Nanoparticle-based hemostasis system
- Nanoparticle Measurement Instrument Market to Garner USD 13,804.23 Million, Globally, by 2028 at 6.6 % CAGR: The Insight Partnerson May 5, 2022 at 10:09 am
The nanoparticle measurement instrument market is projected to reach US$ 13,804.23 million in 2028 from an estimated value of US$ 8,802.26 million in ...
- Clinical Diagnostics & Researchon May 4, 2022 at 5:01 pm
The 7th annual Clinical Diagnostics & Research conference is now On Demand! This premiere venue discusses the latest advances in clinical diagnostics, research and medicine. The conference has proven ...
- Nanoparticles are the future of medicine – researchers are experimenting with new ways to design tiny particle treatments for canceron May 4, 2022 at 4:04 pm
Magnetic resonance imaging, or MRI, often uses nanoparticles as contrast agents that help make an image more visible. Several nanoparticle-based drugs have been approved ... treatments that stimulate ...
- Hold On Tight: Permanent Attachment of Proteins to Nanoparticles for Potential HIV Vaccine Therapyon April 29, 2022 at 5:00 pm
While nanoparticle-based delivery of proteins to areas of ... the protein sticking out like tentacles (pictured). When this system was tested with a vaccine delivery agent (adjuvant) and a ...
- Researchers Show How Nanoparticles May Turn Sunlight into Alternate Forms of Energyon April 27, 2022 at 6:20 am
Novel technologies to convert sunlight into power and fuels will be enabled by new materials. These materials are made possible by the combination of molecules and nanoparticles.
- Excitable Nanoparticles Destroy Endometriosis Lesionson April 24, 2022 at 5:00 pm
Researchers at Oregon State University developed a nanoparticle system that can aid with the removal of endometrial lesions in a minimally invasive fashion. In endometriosis, endometrial tissue ...
- Hydrogel Nanocomposite Designed to Tackle Wound Hemorrhageon April 20, 2022 at 10:03 pm
Recent studies have demonstrated that nanoparticles (NPs ... endogenous hemostasis pathway activation, and cooperating with physical hemostatic performance. Thus, a Laponite nanoclay-gelatin-based ...
- Evidence-based Complementary and Alternative Medicine: eCAMon February 4, 2022 at 8:00 am
Isolation and Identification of Compounds from Bioactive Extracts of Taraxacum officinale Weber ex F. H. Wigg. (Dandelion) as a Potential Source of Antibacterial Agents.
- Microbiology Virtual Week 2020on January 15, 2022 at 6:17 am
Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts. Call for Posters — Virtual poster ...
via Bing News